Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 26 01 2019
accepted: 10 07 2019
pubmed: 19 7 2019
medline: 7 2 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Several clinical studies have reported that renal impairments are sometimes observed in patients with primary aldosteronism (PA). We analyzed the prevalence of renal impairments in PA patients and identified parameters that increase the risk for them. This is a retrospective cross-sectional study. We assessed the PA database established by the multicenter Japan PA study (JPAS). Data were also collected from patients with essential hypertension (EHT). We compared the prevalences of proteinuria and lowered estimated glomerular filtration rate (eGFR) between patients with PA and age, sex, blood pressure and duration of hypertension-matched patients with EHT. We also performed logistic regression analysis to identify parameters that increase the risk for these renal impairments. Among 2366 PA patients, the prevalences of proteinuria and lowered eGFR were 10.3 and 11.6%, respectively. The prevalence of proteinuria was significantly higher in PA patients than matched-EHT patients (16.8 vs 4.4%), whereas there was no significant difference in the prevalence of lowered eGFR (17.2 vs 15.0%). The logistic regression analysis also showed that the plasma aldosterone concentration (PAC) significantly increases the risk of proteinuria and lowered eGFR, independent of other known risk factors. Plasma aldosterone levels are closely associated with renal impairment in patients with PA. This is contrast to our earlier finding that the PAC was not itself linearly associated with cardiovascular events such as stroke or ischemic heart disease. The mechanism underlying the kidney damage in patients with PA may differ from that affecting the cardiovascular system.

Identifiants

pubmed: 31319380
doi: 10.1530/EJE-19-0047
pii: EJE-19-0047.R2
doi:
pii:

Substances chimiques

Biomarkers 0
Aldosterone 4964P6T9RB

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

339-350

Auteurs

Akiyuki Kawashima (A)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Masakatsu Sone (M)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Nobuya Inagaki (N)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Yoshiyu Takeda (Y)

Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

Hiroshi Itoh (H)

Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Tokyo, Japan.

Isao Kurihara (I)

Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Tokyo, Japan.

Hironobu Umakoshi (H)

Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Takamasa Ichijo (T)

Department of Endocrinology and Metabolism, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.

Takuyuki Katabami (T)

Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Japan.

Norio Wada (N)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan.

Yoshihiro Ogawa (Y)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.

Junji Kawashima (J)

Department of Metabolic Medicine, Faculty of Life Science, Kumamoto University, Kumamoto, Japan.

Megumi Fujita (M)

Division of Nephrology and Endocrinology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

Shozo Miyauchi (S)

Department of Diabetes and Endocrinology, Ehime Prefectural Central Hospital, Matsuyama, Japan.

Shintaro Okamura (S)

Department of Endocrinology, Tenriyorozu Hospital, Tenri, Japan.

Tomikazu Fukuoka (T)

Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan.

Toshihiko Yanase (T)

Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Shoichiro Izawa (S)

Department of Endocrinology and Metabolism, Tottori University Hospital, Yonago, Japan.

Yuichiro Yoshikawa (Y)

Department of Endocrinology and Diabetes Mellitus, isato Kenwa Hospital, Misato, Japan.

Shigeatsu Hashimoto (S)

Division of Nephrology, Hypertension, Endocrinology, and Diabetology/Metabolism, Fukushima Medical University Hospital, Fukushima, Japan.

Masanobu Yamada (M)

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan.

Tatsuya Kai (T)

Department of Cardiology, Saiseikai Tondabayahsi Hospital, Tondabayashi, Japan.

Tomoko Suzuki (T)

Department of Public Health, School of Medicine, International University of Health and Welfare, Narita, Japan.

Mitsuhide Naruse (M)

Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Center of Endocrine Diseases, Takeda General Hospital, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH